SGMT
Sagimet Biosciences Inc.Healthcare·Biotechnology
$7.29
$238M market cap
Revenue
$0.0M
Free Cash Flow
$-20.4M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, In
2-Year Price History
$7.09+50.9%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -11.7 | -11.7 | -10.7 | -8.6 | -8.6 | -0.0 | 104.5 | 0.0 | 32.6 | -175.1% | -- | -- |
| Act | 2025-Q4 | 0.0 | -12.2 | -10.8 | -9.6 | -11.8 | -11.8 | -0.0 | 113.1 | 0.1 | 32.4 | -118.7% | -- | -- |
Valuation & Metrics
Market Stats
Price$7.29
Market Cap$238M
Enterprise Value$133M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-8.6%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-20.2M
Free Cash Flow$-20.4M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-146.9%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares4.5M
Days to Cover1.0
Change (vs Prior)+26.0%
Need at least 2 settlement dates for chart
Employees
Headcount14
Revenue / Employee$0
Gross Profit / Employee$0
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
23.5%(+7.9% YoY)
74 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
6.5%(+2.8% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
0.4%(+0.1% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $5.7M | $5.23 | +$5.7M | +$5.7M | — | $4.04T |
| Woodline Partners LP | $5.2M | $7.76 | +$0 | +$5.2M | -0.1% | $26.43B |
| MARSHALL WACE, LLP | $5.0M | $5.20 | +$972K | +$4.9M | +0.6% | $92.71B |
| BAKER BROS. ADVISORS LP | $5.0M | $7.31 | +$0 | +$0 | -0.4% | $16.13B |
| Affinity Asset Advisors, LLC | $4.5M | $6.21 | −$1.5M | +$4.5M | +0.6% | $1.60B |
| MILLENNIUM MANAGEMENT LLC | $4.5M | $5.68 | +$1.4M | +$3.7M | -0.5% | $127.40B |
| BlackRock, Inc.Passive | $4.2M | $3.69 | −$73K | −$893K | -0.2% | $5.69T |
| HHLR ADVISORS, LTD. | $3.8M | $8.80 | +$0 | +$0 | -1.5% | $1.67B |
| RENAISSANCE TECHNOLOGIES LLC | $3.3M | $5.68 | +$1.5M | +$3.3M | +1.2% | $63.91B |
| D. E. Shaw & Co., Inc. | $2.2M | $7.02 | −$387K | +$2.2M | -0.3% | $118.02B |
| Blue Owl Capital Holdings LP | $1.7M | $5.41 | −$4.8M | −$5.2M | -2.3% | $372M |
| RAYMOND JAMES FINANCIAL INC | $1.7M | $3.59 | +$164K | −$150K | -0.0% | $322.69B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $1.6M | $5.68 | +$71K | +$239K | +2.3% | $1.61T |
| Hudson Bay Capital Management LP | $1.6M | $5.92 | −$7K | +$1.6M | +1.9% | $15.12B |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $1.6M | $6.02 | +$0 | +$915K | -2.3% | $4.93B |
| UBS Group AG | $1.5M | $4.70 | +$482K | −$964K | -0.3% | $562.11B |
| DIMENSIONAL FUND ADVISORS LPPassive | $1.4M | $5.44 | +$707K | +$1.3M | -0.4% | $480.92B |
| Pale Fire Capital SE | $1.2M | $5.81 | +$0 | +$1.1M | +0.7% | $1.14B |
| Point72 Asset Management, L.P. | $980K | $5.39 | +$61K | −$8.2M | +0.9% | $54.88B |
| Qube Research & Technologies Ltd | $955K | $5.65 | +$373K | +$776K | +0.3% | $70.36B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-0.15%
avg per quarter
Holders (ex-self)
-0.14%
excl. this stock
Buyers (this Q)
+0.29%
33 buyers · $0.01B in
Sellers (this Q)
-1.10%
20 sellers · $0.01B out
alpha coverage: 90% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-7.1%
how holders react when this stock falls
On quiet Qs
-29.0%
−10% to +10% baseline
On rallies (+10%+)
-7.9%
how they react when this stock rises
Holders' portfolio flow this Q
-0.9%
outflows — trims may be forced
Sellers' portfolio flow this Q
-26.0%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-9.1%
Holder mid (any stock)
-9.7%
Holder rally (any stock)
-10.3%
Biggest decreases this quarter
Blue Owl Capital Holdings LP−$4.8Mα-2.3Siren, L.L.C.exited−$4.3MAffinity Asset Advisors, LLC−$1.5Mα+0.6Verition Fund Management LLCexited−$916KD. E. Shaw & Co., Inc.−$387Kα-0.3HighTower Advisors, LLCexited−$220KLighthouse Investment Partners, LLCexited−$135KDekaBank Deutsche Girozentraleexited−$125KJefferies Financial Group Inc.exited−$78KBlackRock, Inc.−$73Kα-0.2
New buyers this quarter
Top-5 holders · 36.6%
VANGUARD CAPITAL MANAGEMENT LLC--
Woodline Partners LP--
MARSHALL WACE, LLP--
BAKER BROS. ADVISORS LP--
Affinity Asset Advisors, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
NEA Management Company, LLC—FMR LLC148Woodline Partners LP1.0MPoint72 Asset Management, L.P.188KHHLR ADVISORS, LTD.725KBlue Owl Capital Holdings LP334KArtal Group S.A.—BAKER BROS. ADVISORS LP953KAffinity Asset Advisors, LLC868KRock Springs Capital Management LP—
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (1 analysts)$8.00970.0%
Current Price$7.29
Analyst Ratings
6
1
Buy: 6Hold: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$1.17M
8 txns · 5 insiders · 141,898 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-02-10 | SELL | Chauche Thierry | officer: Chief Financial Officer | 1,312 | $5.36 | $7K | $84K |
| 2026-02-10 | SELL | Happel David | director, officer: President & CEO | 12,101 | $5.36 | $65K | $3.63M |
| 2026-02-10 | SELL | Martins Eduardo Bruno | officer: Chief Medical Officer | 3,640 | $5.36 | $20K | $554K |
| 2026-02-10 | SELL | Rozek Elizabeth | officer: Chief Legal & Admin. Officer | 2,622 | $5.36 | $14K | $1.02M |
| 2025-11-20 | SELL | Kemble George | director, officer: Executive Chairman | 37,688 | $7.69 | $290K | $623K |
| 2025-07-21 | SELL | Happel David | director, officer: President & CEO | 65,478 | $9.13 | $598K | $6.30M |
| 2025-07-21 | SELL | Martins Eduardo Bruno | officer: Chief Medical Officer | 8,277 | $9.13 | $76K | $977K |
| 2025-07-21 | SELL | Rozek Elizabeth | officer: General Counsel and CCO | 10,780 | $9.13 | $98K | $1.68M |
Order Flow (FINRA, ~3w lag)
29.0%retail+1.3pp
17.6%dark+0.6pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Sagimet Biosciences: A Clinical-Stage Burn Machine Fueled by Constant Dilution
Overall Risk
6/10
Fraud
2/10
Dilution
9/10
Insolvency
5/10
Earnings Overstated
2/10
Hidden Liabilities
4/10
Legal
2/10
Audit Warnings
4/10
Hidden Upside
7/10
Contextually Acceptable
7/10